trial

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Sublingual Asenapine in a Pediatric Population With Schizophrenia or Bipolar I Disorder (P06522 AM1)

NCTId NCT01206517
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Completed
Enrollment 30 (actual)
Sponsored by Organon and Co
Primary completion 2011-08-04
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Completed
Enrollment
30 (actual)
Study type
Interventional
Allocation
Non Randomized
Model
Parallel
Masking
None
Start
2010-07-18
Primary completion
2011-08-04
Eligibility
ALL · 10 Years · 17 Years

Interventions & indications

Drugs
Asenapine

Sponsors

Organon and CoLead Sponsor

Sites

0 total

Facts & assertions

4 sourced
Enrollment
30
Phase
PHASE1
Primary Completion Date
2011-08-04
Status
COMPLETED
relationships
The graph out of here
drug
Asenapine
drug
lead_sponsor
Organon and Co
company
indication
Schizophrenia
indication
Schizophrenia
indication
Bipolar I Disorder
indication